A phase 3 clinical trial of tivanisiran failed to meet the primary endpoint in the treatment of dry eye disease associated with Sjörgren’s syndrome, according to a press release from Sylentis.
The primary endpoint of the randomized, double-masked, placebo-controlled trial was the evaluation of tivanisiran’s efficacy, including signs and symptoms.
Tivanisiran is based on RNA interference and administered as preservative-free eye drops. The drug selectively inhibits production of the transient receptor potential cation channel, which mediates transmission of ocular pain,